Overview

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

Status:
Completed
Trial end date:
2021-04-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if selinexor will improve the blood counts and bone marrow function in people with your type of MDS.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Columbia University
Karyopharm Therapeutics Inc
Karyopharm Therapeutics, Inc
M.D. Anderson Cancer Center